Department of Health and Human Services, through National Institutes of Health, awarded Immport Therapeutics Inc of Irvine, CA $592,254 under the SBIR program (Phase II), with work starting 2025-08-25 and running to 2027-07-31. It is one of 4 SBIR and STTR awards Immport Therapeutics Inc received in the last two years, $1,792,254 in all. Each figure links to the federal record.
The award
| Recipient | Immport Therapeutics Inc (Irvine, CA) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase II |
| Amount obligated | $592,254 |
| Period of performance starts | 2025-08-25 |
| Period of performance ends | 2027-07-31 |
| Award number | R43AI195168 (grant, CFDA 93.855) |
| Assistance listing | 93.855, Allergy and Infectious Diseases Research |
| Place of performance | Irvine, Orange County, CA |
| Recipient registry id (UEI) | ZJAMPJY7M149 |
Want the whole picture on Immport Therapeutics Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Immport Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Immport Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
A sensitive and specific serology test for evaluating potency of whole cell pertussis vaccines - whooping cough (pertussis) is a highly contagious respiratory disease caused by the gram-negative bacterium, bordetella per
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-08-06 | Continuation | 000 | $292,254 |
| 2025-08-25 | New | 000 | $300,000 |
A sensitive and specific serology test for evaluating potency of whole cell pertussis vaccines - whooping cough (pertussis) is a highly contagious respiratory disease caused by the gram-negative bacterium, bordetella pertussis. In most of the world, infants receive a whole cell pertussis (wp) vaccine in conjunction with diphtheria and tetanus (dtwp). With tens of millions of doses of dtwp administered globally each year, evaluation of vaccine potency is a critical step for manufacturers toward vaccine release. First established in 1947 and still in use today, the kendrick assay is the method of evaluating wp potency. As a labor intensive and highly variable mouse intracerebral challenge protocol, the kendrick assay constitutes a bottleneck in dtwp vaccine release. There have been efforts to replace the kendrick assay with a pertussis serology potency test (pspt) based on a whole pertussis bacteria elisa, but the pspt suffers from issues of sensitivity and variability. Antigen discovery, inc. And dr. Nicholas mantis and colleagues at the division of infectious diseases, wadsworth center, new york state department of health are collaborating in an effort to develop a pspt based on discovery of new b. Pertussis antigens that may serve as indicators of wp vaccine potency. In the proposed study, a b. Pertussis proteome microarray will be developed to identify serological markers ass ...
From the federal award record.
Other SBIR and STTR awards to Immport Therapeutics Inc
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2026-09-09 | Department of Health and Human Services | SBIR Phase I | $300,000 | Identification of protective human monoclonal antibodies for passive immunization against (record) |
| 2026-08-26 | Department of Health and Human Services | SBIR Phase II | $300,000 | Discovery of group a streptococcus antigens for development of broadly effective vaccine c (record) |
| 2025-08-12 | Department of Health and Human Services | SBIR Phase I | $600,000 | Optimizing immunogenicity of novel cryptosporidium vaccine candidates - cryptosporidiosis (record) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Immport Therapeutics IncLook up Immport Therapeutics Inc and see what is on record before you decide.
Get the free SnapshotWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.